Clinical studies with ropinirole in Parkinson's disease and RLS (Journal of Neurology (2006) 253, Suppl. 4, (IV/16-IV/21) DOI: 10.1007/s00415-006-4004-4);Clinical studies with ropinirole in Parkinson's disease and RLS

Journal of Neurology

Volumn 253, Issue SUPPL. 4, 2006, Pages 1444-

  Jost, Wolfgang H ^a   Angersbach, Dieter ^b   Rascol, Olivier ^c  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Dopamine agonists; Parkinson's disease; Ropinirole

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE;

CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE DURATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG RELEASE; EDEMA; HALLUCINATION; HUMAN; META ANALYSIS; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 33748317921     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0082-9     Document Type: Erratum

References (33)

1. Adler CH, Sethi KD, Hauser RA, et al. (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393-399
2. Adler CH, Hauser RA, Sethi K, et al. (2004) Ropinirole for restless legs syndrome. Neurology 62:1405-1407
3. Allen R, Becker PM, Bogan R, et al. (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27:907-914
4. Bogan RK, Fry JM, Schmidt MH, et al. (2006) Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81:17-27
5. Brooks DJ, Torjanski N, Burn DJ (1995) Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 45(Suppl):231-238
6. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 21:101-107
7. Brunt ER, Brooks DJ, Korczyn AD, et al. (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 109:489-502
8. Cheer SM, Bang LM, Keating GM (2004) Ropinirole. For the treatment of restless legs syndrome. CNS Drugs 18:747-754
9. Clarke CE, Deane KHO (2001) Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2:CD001517
10. Elble RJ (2002) Tremor and dopamine agonists. Neurology 58(Suppl 1):S57-S62
11. European Agency for the Evaluation of Medical Products (EMEA). "Rotigotine: Scientific Discussion". released in February 2006
12. Etminam M, Gill S, Samii A (2003) Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease. Drug Safety 26:439-444
13. Freeman A, Rye DB, Bliwise D, Krulewicz S, Watts RL (2001) Ropinirole for the restless legs syndrome (RLS): an open-label and double-blind placebo-controlled study. Neurology 56(Suppl 3):A5
14. Garcia-Borreguero D, Odin P, Schwarz C (2004) Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 109:303-317
15. Giménez-Roldán S, Esteban EM, Mateo D (2001) Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different doseration. Clin Neuropharmacol 24:346-351
16. Im JH, Ha JH, Cho IS, Lee MC (2003) Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. A 16-week bromocriptine controlled study. J Neurol 250:90-96
17. Inzelberg R, Schechtman E, Nisipeanu O (2003) Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease. Drugs Aging 20:847-855
18. Joo-Hyuk I, Jeong-Ho H, In-Sook C, Myoung CL (2003) Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease. A 16-week bromocriptine controlled study. J Neurol 250:90-96
19. Jost WH (1999) Equivalent doses of ropinirole and bromocriptine. Eur J Neurol 6:618
20. Kakar RS, Kushida CA (2005) Ropinirole in the treatment of restless legs syndrome. Expert Rev Neurotherapeutics 5:35-42
21. Konofal E, Arnulf I, Lecendreux M, Mouren MC (2005) Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Ped Neurol 32:350-351
22. Korczyn AD, Brooks D, Brunt ER, Poewe WH, Rascol O, Stocchi F (1998) Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 13:46-51
23. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 53:364-370
24. Lieberman A, Olanow CW, Sethi K, et al. (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51:1057-1062
25. Matheson AJ, Spencer CM (2000) Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 60:115-137
26. th Annual Meeting of the American Academy of Neurology, San Diego, CA, USA, April 1-8:2006
27. Pellecchia T, Vitale C, Sabatini M, et al. (2004) Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis. An open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 27:178-181
28. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491
29. Rascol O, Brooks DJ, Brunt ER, et al. (1998) Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5 year levodopa-controlled study. Mov Disord 13:39-45
30. Rascol O, Korczyn AD, De Deyn PP, Lang AE (2005) Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson's disease initially receiving ropinirole compared with L-dopa. Mov Disord 20(Suppl 10):S63
31. Sethi KD, O'Brien CF, Hammerstad JP, et al. (1998) Ropinirole for the treatment of early Parkinson disease. Arch Neurol 55:1211-1216
32. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. (2004) Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75:92-97
33. Walters AS, Ondo WG, Dreykluft T, et al. (2004) Ropinirole is effective in the treatment of restless legs syndrome. Mov Disord 19:1414-1423